Immunic (NASDAQ:IMUX) Downgraded to Hold Rating by D. Boral Capital

Immunic (NASDAQ:IMUX) was downgraded by analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research report issued on Wednesday, MarketBeat Ratings reports.

A number of other research firms also recently issued reports on IMUX. HC Wainwright reduced their price objective on Immunic from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, March 2nd. Guggenheim began coverage on Immunic in a research note on Tuesday, March 24th. They issued a “buy” rating and a $7.00 price objective on the stock. raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.17.

Immunic Trading Down 3.3%

Shares of IMUX opened at $1.18 on Wednesday. The business’s 50 day moving average is $1.06 and its 200 day moving average is $0.83. The company has a market capitalization of $153.94 million, a PE ratio of -1.69 and a beta of 1.37. Immunic has a 12-month low of $0.51 and a 12-month high of $1.51.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities research analysts predict that Immunic will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

A number of large investors have recently bought and sold shares of IMUX. Jane Street Group LLC boosted its holdings in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after acquiring an additional 152,726 shares during the period. HB Wealth Management LLC purchased a new position in Immunic during the 3rd quarter valued at $81,000. Vanguard Group Inc. boosted its holdings in Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after acquiring an additional 219,957 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Immunic in the 3rd quarter worth $170,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Immunic in the 3rd quarter worth $239,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.